Background: The spore is the virulence factor identified to be involved in the recurrence of the disease caused by Clostridium difficile.
Introduction
The increase in Clostridium difficile infection (CDI) rates is the result of a lack of regulation of the use of broad-spectrum antibiotics (i.e. cephalosporins and quinolones) in hospitals, which causes significant dysbiosis of the colonic microbiota, allowing C. difficile colonization. 1 The main factors involved in the initiation and recurrence of CDI include: (i) C. difficile spores, which are impermeable to antibiotics and to the host's immune system, 2 and play an essential role in the initiation and recurrence of infections; 3 and (ii) an altered state of the microbiota that contributes to C. difficile spore germination and colonization via mechanisms that have not been fully explained. 4 C. difficile's ability to persist in the host is a major contributory factor to the high rate of recurrence of CDI, which may reach up to 20%, 40% and 60% after a first, second and third episode, respectively. 5 Although C. difficile spores play a major role in overcoming the bactericidal effects of antibiotics and promoting a first or recurrent episode of CDI, the existence of additional determinants that contribute to these phenomena cannot be excluded. In this regard, the generation of antibiotic-tolerant persister cells may provide C. difficile with an advantage to outgrow the microbiota after antibiotic therapy. Persister-cell formation is the result of a phenotypic switch that can be triggered during all stages of growth as a response to different types of stresses. This is thought to depend on an increase/reduction in the intracellular concentrations of key molecules that lead to a non-growing (dormant) or reduced growth state. 6 Considering that antibiotic treatment induces dysbiosis of the commensal microbiota and favours C. difficile colonization, 1 we hypothesize that antibiotic treatment could induce the appearance of persister cells of C. difficile, as observed for other pathogenic bacteria. 6 
Materials and methods

MIC determination
Using an epidemic and hypervirulent 027 strain (R20291) 7 and a virulent and MDR laboratory reference strain (630) as models, 8 we determined the MICs of broad-spectrum antibiotics (pefloxacin and cefalexin) and an antibiotic used for the treatment of CDI and recurrent CDI (vancomycin). Briefly, the MICs for C. difficile were determined using the CLSI-recommended agar dilution method for anaerobes. 9 MICs were determined at least in duplicate 
Persister-cell generation
The two C. difficile strains, R20291 and 630, were grown anaerobically in BHIS at 37 C in an anaerobic chamber (Bactron 300, Shellab, USA). Considering that persisters are highly antibiotic-tolerant variants of normal cells that form stochastically in microbial populations, we tested the appearance of persister cells for R20291 and 630 strains under lethal concentrations of selected antibiotics as described previously 10 with some modifications. Exponential cultures in BHIS medium were treated with up to 10% the MIC of each antibiotic and live cell counts at the given timepoints (0, 12, 24, 48, 96 and 144 h) were determined as follows: 10 lL of culture was removed from the flask and centrifuged at 10 000 g for 1 min. The resulting pellet was suspended in PBS. Serial dilutions were performed and 10 lL of each dilution was plated onto BHIS agar plates. Plates were incubated anaerobically at 37 C. At the end of each experiment, cultures were centrifuged and the cell pellets were resuspended in fresh medium and used to set up fresh overnight cultures. Each experiment was repeated up to four times. To ensure that the persister cell-like phenotype was not due to the presence of C. difficile spores, all experiments were performed in an asporogenous spo0A background for R20291 and 630 strains.
4,11
Results and discussion
The R20291 and 630 strains were resistant to both broadspectrum antibiotics and susceptible to vancomycin (Table 1) . Taking into account the initial MIC results (see Table 1 ), we tested for the generation of persister cells using a modification of a previously described method. 10 In this study, we used two broadspectrum antibiotics, a quinolone (pefloxacin) and a cephalosporin (cefalexin), and an antibiotic used for the treatment of C. difficile infections that has been associated with recurrence (vancomycin). The results showed that all antibiotics used were able to induce the appearance of persister-like behaviour since biphasic killing curves could be observed with both of the strains taken into consideration and in response to treatment with all of the antibiotics reported above. In addition, a similar behaviour was observed when culture samples collected at the endpoint of the experiments were used to repeat the experiments (Figure 1a-c) . These observations suggest that the cells that survived antibiotic killing are persisters rather than antibiotic-resistant mutants. In a spo0A R20291 background we did not observe differences with respect to WT R20291 persister formation (Figure 1d-f) , which strongly suggests that those cells are not spores. Moreover, post-treatment MICs of vancomycin were identical to the original MICs. Similar results were obtained for the C. difficile 630 strain [ Figure S1 (available as Supplementary data at JAC Online) and Table 1 ]. The number of viable cells after 6 days of treatment varied between 10 000 and 100 000 cells (log 10 " 4-5), as determined by colony plate count. Considering that initial culture before treatment has 100 000 000 viable cells (log 10 " 8), the final viable cell count equals 0.01%-0.1% that of the initial culture. This number correlates with those of several authors, who show that persister cells represent 0.001%-0.1% of the total population. 6, 12 Moreover, in a spo0A background the same behaviour was observed, which permits us to speculate that those cells are not spores.
The importance of persister cells in the recalcitrance of several infectious diseases to antibiotic therapy has been demonstrated in several pathogens. Salmonella, Escherichia coli, Pseudomonas aeruginosa and Mycobacterium tuberculosis, for instance, are all capable of inducing persister-cell formation in laboratory growth medium under lethal antibiotic concentrations. 13 Other studies have demonstrated that isolates taken from a cystic fibrosis lung exhibited a lower frequency of appearance of persisters than those isolates taken after repetitive rounds of antibiotic therapy.
14 This strongly indicates that persister cells will be ubiquitously present in a bacterial community, suggesting a common strategy of persistence, where bacteria ensure that some cells enter a dormant state when environmental stressors appear, safeguarding the conservation of the progeny.
In accordance with our results, the appearance of C. difficile persister-like cells is more likely to contribute to the initiation of the disease rather than to recurrent infection. In this context, it is conceivable that a phenotypic switch associated with the appearance of antibiotic-tolerant persister C. difficile cells, probably associated with biofilm, 15 might provide an advantage to outgrow the microbiota after antibiotic therapy, leading to the initiation of the disease. However, despite our evidence that asporogenous C. difficile strains (i.e. spo0A mutants) are able to form persister-like cells, Deakin et al. 3 demonstrated that the C. difficile spo0A mutant was unable to cause recurrent disease in a mouse model of recurrence, 3 suggesting that persister-like cells, even if formed in vivo, do not contribute to recurrence. Importantly, there are no studies linking the appearance of persister cells with initiation of CDI. In this report, we have shown that Non-spore Clostridium difficile persister-like cells JAC antibiotics that induce dysbiosis and antibiotics used for treatment could trigger the formation of persister cells, at least in vitro, suggesting that antibiotic treatment may promote C. difficile colonization inducing CDI in vivo. In summary, the ability of C. difficile persister-like cells to participate in the initiation of infections needs to be investigated. Indeed, this could lay the foundations for the development of alternative therapies against CDI, which would specifically focus on the eradication of persisters. According to Kim and Wood, 16 persister cells survive antibiotic treatment due to their lack of metabolism, rather than through genetic change. Unfortunately, the literature produced from over seven decades of persister-cell research has been populated by misperceptions that do not withstand scrutiny. Á lvarez et al.
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